← All trials
NCT03108482
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 13, 2017
- Primary completion
- Sep 13, 2017
- Completion date
- Sep 20, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 630
- Arms / groups
- 4 / —
- Source
- AACT · pre-existing
Sponsors
- Esteve LabsLead sponsor
- Chesapeake Research Group, LLCOverall official - principal investigator
- Premier Research GroupStudy chair
- Premier Research GroupCollaborator
- Esteve LabsStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.